Haemonetics' Triple Play: Plasma, IVT, and Cash Flow Spark a 90% Rally
Persona PLUS adoption and a return to growth in Interventional Technologies drive a raised outlook and a surge in free cash flow.
HAE · Earnings Call · 2026-08-06
The Setup: A Clean Print That Inflects the Tape
Since the April trough, Haemonetics has added roughly 90% in 90 trading days, and the fiscal Q1 report released August 6th offers the fundamental confirmation the tape was waiting for. The company started FY '27 with “broad-based execution driving another quarter of profitable growth,” — Christopher Simon, Chief Executive Officer (CEO) · 2026-08-06 reporting revenue of $339M (+6% reported and organic) and adjusted EPS of $1.14. More important, management raised full-year revenue guidance to 5%–8% reported and 4%–7% organic — a signal that the momentum is durable, not a one-off beat. The commentary is sprinkled with the kind of language that typically accompanies a de-risked setup: “triple-play,” “trifecta,” and the phrase Interventional Technologies “returned to growth.” On the call, CEO Chris Simon said the quarter reflected strength across Plasma, Blood Management Technologies, and Interventional Technologies, but the real engine is the software-and-disposable flywheel now turning in Plasma and the long-awaited stabilization in Vascular Closure.The Engine: Plasma and Persona PLUS
The Plasma franchise delivered 6% organic growth, with disposables up double digits globally and North American disposables up in the mid-20s. The driver, as management framed it, is Persona PLUS adoption. The simple firmware upgrade that increases donor yield by ~5% over earlier Persona versions is rolling out faster than expected; Chris Simon said the company is converting “30 or 40 centers a week” — Christopher Simon, Chief Executive Officer (CEO) · 2026-08-06 without pushback. This is not just volume growth — it's margin-accretive and reinforces the customer stickiness that made Plasma the cash engine of the portfolio. This theme was already foreshadowed in prior quarters. In May 2026, Simon described FY '26 as “a record year for plasma” — Christopher Simon, Chief Executive Officer · 2026-05-08 with a “trifecta” of price, share, and volume. The current quarter extends that: raising Apheresis guidance to low-to-mid-single-digit growth, while keeping the conservative 0%–2% collection volume assumption embedded in guidance. That conservatism is telling — it means any upside in collections is pure optionality. Management is also mindful of the external cost environment, including tariffs and fuel. James D'Arecca flagged a $7M tariff refund in Q2 but cautioned it would be largely offset by higher oil, transportation, and material inflation — a nuanced stance that shows the company is not banking on one-time tailwinds.The Recovery: IVT, Vascular Closure, and PerQseal
The most anticipated turnaround is in Interventional Technologies, which returned to growth after a disappointing FY '26. Vascular Closure led the way, growing low-double-digits, and “reflected a better market backdrop. We now see PFA at somewhere between 80% and 85% penetration. That's effectively stabilizing the access site growth rate” — Christopher Simon, Chief Executive Officer (CEO) · 2026-08-06 — eliminating the headwind that had depressed the segment. Simon attributed the rebound to three factors: a resumption of access site growth, stronger commercial execution from sales and marketing investments, and the momentum from the VASCADE MVP XL expanded indication. As he put it, “The label expansion that we received from FDA earlier this fiscal year has really opened the door for us.” The pipeline adds further upside: PerQseal Elite — the large-bore closure product from the Vivasure acquisition — is in dialogue with the FDA, and management has deliberately excluded any revenue from that launch in guidance. This creates a potential catalyst if approval lands within the fiscal year.Financial Strength and an Improved Earnings Algorithm
The quarter also underscored the earnings power of the model. Gross margin at 60.4% was down 40bps year-over-year but only because of a prior-year software benefit; ex-software, margins expanded. Operating margin was 23.4%, and management reaffirmed 50–100bps of full-year expansion. Free cash flow was the standout: “Free cash flow conversion reached 75% of adjusted net income, an exceptional result for what is typically our seasonally weakest net cash inflow quarter.” — James D'Arecca, Chief Financial Officer (CFO) · 2026-08-06 Over the last twelve months, conversion hit 106%.That cash is being put to work: $50M revolver paydown during the quarter, another $50M after quarter-end, and a balanced approach to buybacks. The balance sheet is cleaning up while still funding R&D and the launch pipeline. We should place this in a broader context. Haemonetics is now a mid-cap with a market cap near the low-$3B range, but the stock is trading at a discount to the market on a normalized earnings basis. The free cash flow margin has gone from negative a few years ago to ~13% trailing, and the conversion rate suggests the GAAP earnings are understated by the heavy amortization and one-time charges that have weighed on net income. The guidance raise — even while keeping conservative assumptions on collection volume and excluding PerQseal — gives the market a clean story: a company that has finally lapped its legacy overhangs, is growing organically in the mid-to-high single digits, and is converting at 80%+ of adjusted net income. The 90% rally in three months reflects not just the beat but the removal of the “but for” language that had characterized prior quarters. As Simon said on the call, “The fog is clearing and it's going to reveal the forest for the trees” — and the market is paying up for that visibility. From a keyword perspective, the themes now resonating are return to growth in IVT, VASCADE MVP XL driving share, and IEEPA tariff refund as a modest tailwind. But the real signal is that the company has moved from defense to offense: raising guidance, converting cash, and building a launch pipeline that could extend the story into next year.Strong earnings once again translated into strong cash generation, reinforcing both the quality of our earnings and the durability of our operating model.